Patents Issued in November 7, 2017
-
Patent number: 9809616Abstract: The compounds are of the class of N4-hydroxycytidine nucleosides, modified monophosphate and phosphonates prodrugs analogs, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof, useful in treating HCV or Norovirus infections.Type: GrantFiled: October 29, 2013Date of Patent: November 7, 2017Assignees: Emory University, Cocrystal Pharma, Inc.Inventors: Franck Amblard, Steven J. Coats, Raymond F. Schinazi
-
Patent number: 9809617Abstract: The present invention relates to the field of medicinal chemistry, and discloses a new crystal form of regadenoson, i.e., a crystal form E of regadenoson, as well as a method for preparing the new crystal form of regadenoson. The crystal form E of regadenoson according to the present invention has excellent performances in terms of radionuclide myocardial perfusion imaging, and has a poor toxicity, good storage stability, and can be used in the preparation of a medicament used as a stress agent for radionuclide myocardial perfusion imaging.Type: GrantFiled: July 3, 2015Date of Patent: November 7, 2017Assignee: Shanghai Ziyuan Pharmaceutical Co., Ltd.Inventors: Wei Liu, Zhigang Zhang, Qin Bao
-
Patent number: 9809618Abstract: A new process for enriching triterpene esters comprising: providing a mixture comprising a non-distilled vegetable oil and/or a non-distilled vegetable fat, further comprising triterpene esters, performing a mild transesterification with a lower alcohol, removing lower alcohol esters by deodorization, physical refining, evaporation or distillation, and recovering the remaining fraction rich in triterpene esters. Triterpene esters enriched with the method as well as uses of the same are also provided. One advantage is that it is a more economically viable way of achieving higher concentration of triterpene esters. There is both the chance to fully keep the natural distribution of triterpene esters but in the other end also to replace the natural level of cinnamic and acetic acids-triterpene esters with a high level of long fatty acid triterpene-esters.Type: GrantFiled: September 30, 2014Date of Patent: November 7, 2017Assignee: AAK ABInventors: Jari Alander, Staffan Norberg, Krister Hed
-
Patent number: 9809619Abstract: Methods for pulse combustion spray drying of heat-sensitive protein compositions using high temperature pulsating jets to atomize and dry the feed simultaneously are described herein. Methods and compositions described herein provide dried protein-containing compositions with low protein denaturation and other useful functional properties at high operational efficiencies.Type: GrantFiled: January 14, 2015Date of Patent: November 7, 2017Assignee: PULSE HOLDINGS, LLCInventors: James A. Rehkopf, David A. Mirko
-
Patent number: 9809620Abstract: Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease.Type: GrantFiled: April 29, 2014Date of Patent: November 7, 2017Assignee: University of SaskatchewanInventors: Kristen Marciniuk, Ryan Taschuk, Scott Napper, Andrew Potter, Neil Cashman
-
Patent number: 9809621Abstract: It is provided PACE4 inhibitors and their uses for treating infection, cancer. Particularly, it is provided a method or use for the treatment of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the PACE4 inhibitors or the composition disclosed.Type: GrantFiled: August 30, 2012Date of Patent: November 7, 2017Assignee: SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C.Inventors: Robert Day, Witold A. Neugebauer, Yves Dory
-
Patent number: 9809622Abstract: A tumor-targeting peptide is disclosed. This tumor-targeting peptide comprises a typical motif with the general formula of: XX(Y/F) (D/E) (D/E) XX. The motif is selectively connected with 1-3 amino acids at the C-terminal and/or N-erminal. X represents any one of the twenty natural amino acids or the D type amino acids. The present invention also discloses that the peptide can not only target tumor vessels and tumor cells but also penetrate them and thus can be applied in tumor diagnosis and therapy.Type: GrantFiled: September 5, 2014Date of Patent: November 7, 2017Assignee: Sun Yat-Sen University Cancer CenterInventors: Musheng Zeng, Xing Zhang, Jun Wang, Guokai Feng, Mengqing Zhang, Qian Zhong
-
Patent number: 9809623Abstract: The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against ?4?1 binding, and have high stability under gastrointestinal conditions.Type: GrantFiled: October 1, 2015Date of Patent: November 7, 2017Assignee: Protagonist Therapeutics, Inc.Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Larry C. Mattheakis, David Liu
-
Patent number: 9809624Abstract: The invention relates to a new neurotensin analogue, or a salt thereof, useful for targeting to neurotensin receptor-positive tumors, like ductal pancreatic adenocarcinoma, exocrine pancreatic cancer, invasive ductal breast cancers, colon adenocarcinoma, small cell lung carcinoma, Ewing sarcoma, meningioma, medulloblastoma and astrocytoma.Type: GrantFiled: July 16, 2010Date of Patent: November 7, 2017Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), IASON GmbHInventors: Anne Gruaz, Didier Pelaprat, Jacques Barbet, Dirk Tourwe
-
Patent number: 9809625Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: GrantFiled: March 14, 2016Date of Patent: November 7, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Kenneth M. Boy, Paul Michael Scola
-
Patent number: 9809626Abstract: The invention provides compounds of formula (I): and salts thereof, wherein X and Y have any of the values defined herein. The compounds inhibit bacterial RNA polymerase, inhibit bacterial growth, and have applications in, analysis of RNA polymerase structure and function, control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, antibacterial therapy, and drug discovery.Type: GrantFiled: February 17, 2017Date of Patent: November 7, 2017Assignee: Rutgers, the State University of New JerseyInventors: Richard H. Ebright, Yon W. Ebright, Yu Feng, David Degen
-
Patent number: 9809627Abstract: The present disclosure describes cyclized peptides that inhibit A? toxicity and therefore can be used as therapeutic agents to treat Alzheimer's Disease.Type: GrantFiled: October 15, 2015Date of Patent: November 7, 2017Assignee: Wisconsin Alumni Research FoundationInventors: Regina M. Murphy, Patricia Y. Cho, Jeffrey A. Johnson, Xiaomeng Lu
-
Patent number: 9809628Abstract: The present invention refers to methods for selectively recognizing a base pair in a DNA sequence by a polypeptide, to modified polypeptides which specifically recognize one or more base pairs in a DNA sequence and, to DNA which is modified so that it can be specifically recognized by a polypeptide and to uses of the polypeptide and DNA in specific DNA targeting as well as to methods of modulating expression of target genes in a cell.Type: GrantFiled: July 28, 2016Date of Patent: November 7, 2017Inventors: Ulla Bonas, Jens Boch, Sebastian Schornack, Thomas Lahaye
-
Patent number: 9809629Abstract: Disclosed are hypoallergenic variants of Phl p 5, the major allergen from Phleum pratense, and the uses thereof in the treatment of allergic diseases.Type: GrantFiled: December 18, 2012Date of Patent: November 7, 2017Assignee: LOFARMA S.P.A.Inventors: Giovanni Mistrello, Stefania Zanotta, Daniela Roncarolo
-
Patent number: 9809630Abstract: The present invention is directed to enzyme based methods for separating protein from protein-rich materials derived from plant seeds, fruit, or other biomass and products made therefrom. The protein content in the resulting products is improved by separating and removing the carbohydrates from around the proteins in, for example, soybean meal. This removal is facilitated by the enzymatic hydrolysis of poly- and oligomeric carbohydrates into monosaccharides and other water soluble sugars. The present invention provides for the production of three streams of useful materials. The first is an enriched protein material comparable to the known SPCs but without significant quantities of undigestible oligosaccharides and polysaccharides. The second is an SPI made from the soluble protein in the hydrolysate which is valuable for high-quality feed, food and industrial uses.Type: GrantFiled: May 9, 2013Date of Patent: November 7, 2017Assignee: THE UNIVERSITY OF AKRONInventors: Lu-Kwang Ju, Abdullah Loman, Anthony Coffman, Qian Li, Srujana Koganti
-
Patent number: 9809631Abstract: Lectin compositions and methods for reducing tumor cell growth and preventing or treating cancer are provided.Type: GrantFiled: October 23, 2015Date of Patent: November 7, 2017Inventors: Gary S. Goldberg, Yongquan Shen
-
Patent number: 9809632Abstract: Disclosed herein are chimeric proteins that include one or more double stranded nucleic acid binding domains (dsNABD) and one or more polyHis domains, and compositions that further include a therapeutic double stranded nucleic acid and a targeting ligand bound to the therapeutic double stranded nucleic acid, wherein the dsNABD of the chimeric protein is bound to the therapeutic double stranded nucleic acid, and uses of the compositions to treat disease.Type: GrantFiled: October 22, 2014Date of Patent: November 7, 2017Assignee: University of Washington Through its Center for CommercializationInventors: Xiaohu Gao, Hong Yan Liu
-
Patent number: 9809633Abstract: Peptide-based reagents, compositions and oral care products containing the peptide-based reagents, and methods for using the peptide-based reagents, compositions, or oral care products to treat dental diseases such as periodontitis, tooth erosion, hypersensitivity, bacterial plaque, dental fluorosis, tooth decay, carries, tooth resorption, and gingival recession, are described.Type: GrantFiled: February 4, 2016Date of Patent: November 7, 2017Assignee: University of Washington Through its Center for CommercializationInventors: Mehmet Sarikaya, Martha Somerman, Candan Tamerler-Behar, Hanson Fong, Hai Zhang, Mustafa Gungormus
-
Patent number: 9809634Abstract: Provided are a branched multi-peptide composition and a vaccine including the same. The branched multi-peptide vaccine according to the present invention is easy to be produced and utilized, thereby being easily applied to the treatment, and is capable of maintaining stable reaction in vivo, such that it is expected that the branched multi-peptide vaccine according to the present invention acts as an effective vaccine. Further, for the tumor antigen peptide, the present invention may select an antigen that is largely expressed in a malignant brain tumor. In addition, from now on, it is expected that tumor antigens having a large expression level may be analyzed depending on tumor characteristics of an individual patient, such that the branched multi-peptide vaccine according to the present invention may be utilized for producing personalized branched peptides and vaccines using the same.Type: GrantFiled: December 31, 2015Date of Patent: November 7, 2017Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITYInventors: Tae-Young Jung, Young-Hee Kim
-
Patent number: 9809635Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors.Type: GrantFiled: March 21, 2011Date of Patent: November 7, 2017Assignee: LifeNet HealthInventors: Xiaofei Qin, Silvia Chen, Jingsong Chen, James A. Clagett
-
Patent number: 9809636Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.Type: GrantFiled: March 14, 2013Date of Patent: November 7, 2017Assignee: ACCELERON PHARMA INC.Inventors: Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani, John Knopf
-
Patent number: 9809637Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.Type: GrantFiled: February 16, 2016Date of Patent: November 7, 2017Assignee: ACCLERON PHARMA INC.Inventors: Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
-
Patent number: 9809638Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.Type: GrantFiled: June 2, 2016Date of Patent: November 7, 2017Assignee: Amgen Inc.Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Patent number: 9809639Abstract: Materials and methods for use of constrained cohydration agents in the purification of biological materials such as antibodies, viruses, cells, and cellular organelles in connection with convective chromatography, fluidized bed or co-precipitation applications.Type: GrantFiled: June 1, 2012Date of Patent: November 7, 2017Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventor: Peter Stanley Gagnon
-
Patent number: 9809640Abstract: The present invention provides novel pharmaceutical compositions comprising ApoE-derived peptide dimers. In particular, the ApoE peptide dimers of the invention comprise at least two ApoE mimetic domains and can comprise one or more protein transduction domains. Methods of treating various conditions, such as cancer, inflammatory conditions, and neurodegenerative diseases, by administering the pharmaceutical compositions of the invention are also disclosed.Type: GrantFiled: October 6, 2015Date of Patent: November 7, 2017Assignee: Cognosci, Inc.Inventors: Michael P. Vitek, Dale J. Christensen
-
Patent number: 9809641Abstract: The present invention aims to provide a lactoferrin fusion protein, which is configured to retain the biological activities of natural lactoferrin, to have a significantly prolonged in vivo lifetime, and to be more clinically useful than natural and gene recombinant lactoferrin, as well as a method for preparation thereof, etc. The present invention provides a fusion protein formed with a protein or peptide comprising an FcRn-binding region and lactoferrin or a biologically active fragment or peptide of lactoferrin, which is represented by: (LF-s-Y)n or (Y-s-LF)n [wherein LF represents lactoferrin or a biologically active fragment or peptide of lactoferrin, represents the protein or peptide comprising an FcRn-binding region, s represents ally amino acid sequence of 0 to 10 residues, and n represents an integer of 1 to 10], or a variant thereof.Type: GrantFiled: April 23, 2013Date of Patent: November 7, 2017Assignee: NRL PHARMA, INC.Inventors: Atsushi Sato, Shinji Kagaya
-
Patent number: 9809642Abstract: A transgenic chicken comprising an inactivated heavy immunoglobulin gene and/or inactivated light chain immunoglobulin gene is provided, as well as cells and targeting vectors for making the same.Type: GrantFiled: May 27, 2016Date of Patent: November 7, 2017Assignee: Crystal Bioscience Inc.Inventors: Philip A. Leighton, William Don Harriman, Robert Etches
-
Patent number: 9809643Abstract: Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses.Type: GrantFiled: July 30, 2015Date of Patent: November 7, 2017Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Todd G. Smith, Xianfu Wu
-
Patent number: 9809644Abstract: Antibodies against influenza hemagglutinin, compositions containing the antibodies, and methods of using the antibodies are provided herein.Type: GrantFiled: July 21, 2014Date of Patent: November 7, 2017Assignee: iBio Inc.Inventors: Vidadi Yusibov, Vadim Mett, Jessica Chichester, Lauren Goldschmidt
-
Patent number: 9809645Abstract: [Problem] The present invention addresses the problem of providing an anti-Staphylococcus antibody having preventive or therapeutic effects on staphylococcal infections. [Solution] Provided is an anti-Staphylococcus antibody having preventive or therapeutic effects on staphylococcal infections and a method for manufacturing said antibody, as well as a composition, a product, and a drug containing said antibody. The antibody is obtained by using deacetylated Staphylococcus for immunization.Type: GrantFiled: March 11, 2014Date of Patent: November 7, 2017Assignees: ZENYAKU KOGYO KABUSHIKIKAISHA, Juntendo Educational FoundationInventors: Hiroyoshi Ohsawa, Jumpei Enami, Keiichi Hiramatsu
-
Patent number: 9809646Abstract: The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the nG1m1,2 or Km3 allotypes. The antibodies or fragments may bind to a human histone protein, such as H2B, H3 or H4. The antibodies or fragments are of use to treat a variety of diseases that may be associated with histones, such as autoimmune disease (e.g.Type: GrantFiled: April 14, 2017Date of Patent: November 7, 2017Inventors: Chien-Hsing Chang, Hans J. Hansen, David M. Goldenberg
-
Patent number: 9809647Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: GrantFiled: August 3, 2015Date of Patent: November 7, 2017Assignee: Eisai R&D Management Co., Ltd.Inventors: Toshio Imai, James Bradford Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Patent number: 9809648Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.Type: GrantFiled: December 17, 2012Date of Patent: November 7, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Leonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
-
Patent number: 9809649Abstract: Administration of an antibody that specifically binds IL-1? is useful for treating cachexia and increasing the lifespan of a subject suffering from cachexia.Type: GrantFiled: September 21, 2012Date of Patent: November 7, 2017Assignee: XBIOTECH, INC.Inventor: John Simard
-
Patent number: 9809651Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.Type: GrantFiled: February 18, 2016Date of Patent: November 7, 2017Assignee: BIOCON LIMITEDInventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
-
Patent number: 9809652Abstract: The present disclosure relates to methods of treating individuals suffering from progressive forms of multiple sclerosis.Type: GrantFiled: August 8, 2012Date of Patent: November 7, 2017Assignees: AbbVie Biotherapeutics Inc., Biogen MA Inc.Inventors: Steven Jay Greenberg, Jacob Stephen Broomall Elkins
-
Patent number: 9809653Abstract: Antibodies are provided which specifically bind human and Macaca fascicularis lysosomal-associated membrane protein 1 (LAMP1) proteins and immunoconjugates comprising said antibodies conjugated or linked to a growth inhibitory agent. Pharmaceutical compositions comprising antibodies or immunoconjugates of the invention and use of the antibodies or immunoconjugates for the treatment of cancer are also provided, as well as LAMP1 antibodies, isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies and the use of said antibody as a diagnostic tool. The application further provides for the detection of LAMP1 gene amplification or gain in cancer cells leading to the determination if patients with cancer are likely to respond to anti-LAMP1 therapy. Anti-LAMP1 therapeutic agent for use for treating cancer in a patient harboring LAMP1 gene copy number gain in cancer cells is further provided.Type: GrantFiled: June 26, 2015Date of Patent: November 7, 2017Assignee: SANOFIInventors: Yves Baudat, Francis Blanche, Béatrice Cameron, Tarik Dabdoubi, Anne-Marie LeFebvre, Magali Mathieu, Ana Merino-Trigo, Manoel Nunes
-
Patent number: 9809654Abstract: The invention is directed to a compound comprising one or more CD1d complexes in association with an antibody specific for a cell surface marker. The CD1d complexes comprise a CD1d, a ?2-microglobulin molecule, and may further comprise an antigen bound to the CD1d binding groove. The invention is further directed to methods of inhibiting or stimulating an immune response with the CD1d-antibody compounds, in particular anti-tumor and autoimmunity responses.Type: GrantFiled: September 26, 2003Date of Patent: November 7, 2017Assignee: Vaccinex, Inc.Inventors: Bruno Robert, Alena Donda, Valerie Cesson, Jean-Pierre Mach, Maurice Zauderer
-
Patent number: 9809655Abstract: The invention relates to a method for modifying nanofibrillar cellulose composition, comprising—preparing fibrous dispersion of ionically charged nanofibrillar cellulose (NFC), and—applying heat treatment at a temperature of at least 90° C. to the fibrous dispersion until the viscosity of NFC starts to decrease. The viscosity of the heat-treated NFC is reversible by applying shear forces to the NFC.Type: GrantFiled: June 24, 2014Date of Patent: November 7, 2017Assignee: UPM-KYMMENE CORPORATIONInventors: Antti Laukkanen, Markus Nuopponen, Martina Lille
-
Patent number: 9809656Abstract: Processes for making and using a viscosified liquid slurry polymerization additive are disclosed herein. The process for making a viscosified liquid slurry polymerization additive comprises contacting a polymerization additive with a liquid to form a liquid slurry polymerization additive, and shearing the liquid slurry polymerization additive to increase its viscosity and thus form the viscosified liquid slurry polymerization additive. The process for using a viscosified liquid slurry polymerization additive comprises contacting, under polymerization conditions, in a reactor system: a catalyst system, one or more monomers, and at least one viscosified liquid slurry polymerization additive.Type: GrantFiled: September 25, 2014Date of Patent: November 7, 2017Assignee: Univation Technologies, LLCInventors: Richard B. Pannell, David M. Glowczwski, Chi-I Kuo
-
Patent number: 9809657Abstract: A solution of a mixed alkaline earth alkoxide compound with an aluminum compound in an aprotic solvent, and methods of making and using them.Type: GrantFiled: October 25, 2013Date of Patent: November 7, 2017Assignee: ALBEMARLE GERMANY GMBHInventors: Ulrich Wietelmann, Armin Stoll, Florian Kiefer, Ute Emmel
-
Patent number: 9809658Abstract: Described herein is a method of purifying a product and recycling water comprising the following steps: (i) providing a crude product comprising at least one low molecular weight fluoroorganic compounds wherein the low molecular weight fluoroorganic compounds is partially fluorinated and comprises a polar group and/or a reactive group; (ii) extracting the impurity from the product using water to form an extract, (iii) contacting the extract with a radical-forming process to degrade the low molecular weight fluoroorganic compounds into carbon dioxide, water, fluorine ions, and optionally cations; and (iv) using the water from step (iii) in step (ii)Type: GrantFiled: August 23, 2016Date of Patent: November 7, 2017Assignee: 3M Innovative Properties CompanyInventors: Klaus Hintzer, Michael Juergens, Gunther J. Kaempf, Harald Kaspar, Kai H. Lochhaas, Andre Streiter, Oleg Shyshkov, Tilman C. Zipplies, Herbert Koenigsmann
-
Patent number: 9809659Abstract: A process for the preparation of polyethylene by polymerizing in a slurry ethylene and optionally one or more C3 to C10 alpha-olefins in a reactor system comprising a polymerization reactor and one or more first heat exchangers located outside the polymerization reactor where the slurry in the polymerization reactor is cooled by withdrawing slurry from the polymerization reactor, cooling the slurry in the one or more first heat exchangers and returning the cooled slurry to the polymerization reactor, wherein the one or more first heat exchangers are cooled by a first coolant having a temperature of 29° C. or higher.Type: GrantFiled: June 22, 2015Date of Patent: November 7, 2017Assignee: Basell Polyolefine GmbHInventors: Giuseppe Penzo, Rodrigo Carvajal, Reinhard Kuehl, Elke Damm
-
Patent number: 9809660Abstract: A process for making a low density polymer in a polymerization reactor system, the process comprising polymerizing an olefin monomer, and optionally an olefin comonomer, in the presence of a diluent in a polymerization reactor to make a polymerization product slurry consisting of a liquid phase and a solid phase, wherein the solid phase comprises an olefin polymer having a density of between about 0.905 g/cm3 to about 0.945 g/cm3; and discharging the polymerization product slurry from the polymerization reactor through a continuous take-off valve to make a mixture further comprising a vapor phase. The mixture comprises a pressure less than a bubble point pressure of a component in the polymerization product slurry.Type: GrantFiled: February 22, 2017Date of Patent: November 7, 2017Assignee: Chevron Phillips Chemical Company, LPInventors: John D. Hottovy, Scott E. Kufeld, Joel A. Mutchler
-
Patent number: 9809661Abstract: A process for the continuous synthesis of diene elastomers with a high degree of conversion is provided. The process includes simultaneously: a) introducing continuously into a polymerization reactor containing a gas phase and equipped with at least one stirring rotor and a discharge device, at least i. one or more monomers, including at least one conjugated diene monomer, and ii. from 0% to 70% by mass of an organic solvent, calculated relative to the total mass of monomers and of solvent b) continuously polymerizing the monomer(s), c) stirring the polymerization medium via the continuous movement of at least one stirring rotor about a rotary axle, d) continuously discharging the elastomer paste, e) continuously conveying the discharged elastomer paste to a chopping device and chopping it into particles, f) removing solvent from the particles of the elastomer paste, and g) recovering diene elastomer.Type: GrantFiled: July 1, 2013Date of Patent: November 7, 2017Assignees: COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN, MICHELIN RECHERCHE ET TECHNIQUE S.A.Inventors: Jerome Dussillols, Pierre Kiener, Helene Parola
-
Patent number: 9809662Abstract: Processes for producing a polypropylene product by using a lower purity propylene stream. An operating parameter of the separation zone for a dehydrogenation zone effluent may be adjusted or controlled to lower the purity of the propylene stream produced by the separation zone. The reflux rate of propylene-propane splitter may be reduced. The duty of the reboiler for the propylene-propane splitter may be lowered. The number of stages in the propylene-propane splitter may be decreased.Type: GrantFiled: June 2, 2015Date of Patent: November 7, 2017Assignee: UOP LLCInventors: Adam J. Kanyuh, Michael J. Banach, Robert B. James
-
Patent number: 9809663Abstract: The present invention provides a catalyst component for olefin polymerization and a preparation method thereof, and a catalyst for olefin polymerization and an application thereof. The catalyst component for olefin polymerization comprises reaction products of the following components: (1) a solid component; (2) at least one titanium compound; and (3) at least two internal electron donors, wherein the solid component comprises a magnesium compound represented by formula (1) and an epoxide represented by formula (2), wherein R1 is a C1-C12 linear or branched alkyl; R2 and R3 are identical or different, and are independently hydrogen or unsubstituted or halogen-substituted C1-C5 linear or branched alkyl; X is halogen; m is in a range of from 0.1 to 1.9, n is in a range of from 0.1 to 1.9, and m+n=2.Type: GrantFiled: October 17, 2014Date of Patent: November 7, 2017Assignees: CHINA PETROLEUM & CHEMICAL CORPORATION, BEIJING REAEARCH INSTITUTE OF CHEMICAL INDUSTRY, CHINA PETROLEUM & CHEMICAL CORPORATIONInventors: Xianzhi Xia, Jin Zhao, Weili Li, Yuexiang Liu, Yongtai Ling, Ping Gao, Yang Tan, Futang Gao, Renqi Peng, Jigui Zhang
-
Patent number: 9809664Abstract: This invention relates to high porosity (?15%) and/or low pore diameter (PD<165 ?m) propylene polymers and propylene polymerization processes using single site catalyst systems with supports having high surface area (SA?400 m2/g), low pore volume (PV?2 mL/g), a specific mean pore diameter range (PD=1-20 nm), and high average particle size (PS?30 ?m).Type: GrantFiled: April 29, 2016Date of Patent: November 7, 2017Assignee: ExxonMobil Chemical Patents Inc.Inventors: Luo Lubin, Matthew W. Holtcamp, Gregory S. Day
-
Patent number: 9809665Abstract: A process for production of polyisobutylene includes subjecting a reaction admixture comprising isobutylene, a diluent for the isobutylene, which may be isobutane, and a catalyst composition, that may include a BF3/methanol catalyst complex, to reaction conditions suitable for causing at least a portion of the isobutylene to undergo polymerization to form a polyisobutylene product including polyisobutylene molecules. At least a fraction of the polyisobutylene molecules thus produced have alpha position double bonds and the polyisobutylene product has a number average molecular weight (MN) and a polydispersity index (PDI). The concentration of the diluent in the reaction admixture may be manipulated to control or change any one or more of (a) the relative size of the fraction, (b) the number average molecular weight of the product, (c) the polydispersity index of the product and (d) the relative size of the portion.Type: GrantFiled: March 8, 2011Date of Patent: November 7, 2017Assignee: TPC GROUP LLCInventors: Klaus R. Menschig, Sohel Shaikh, Sathy R. Ponnuswamy, Rex Lawson
-
Patent number: 9809666Abstract: The present invention relates to a polypropylene composition comprising a multimodal propylene random copolymer with at least one comonomer selected from alpha-olefins with 2 or 4 to 8 carbon atoms, wherein the polypropylene composition has a melt flow rate MFR2 (2.16 kg, 230° C.) of 0.05 to 1.0 g/10 min, determined according to ISO 1133, a polydispersity index (PI) of 2.0 to 7.0, and a Charpy Notched Impact Strength at 0° C. of more than 4.0 kJ/m2, determined according to ISO 179/1eA:2000 using notched injection moulded specimens, a process for producing said polypropylene composition, an article comprising said polypropylene composition and the use of said polypropylene composition for the production of an article.Type: GrantFiled: April 22, 2014Date of Patent: November 7, 2017Assignees: ABU DHABI POLYMERS COMPANY LIMITED (BOROUGE), BOREALIS AGInventors: Cristian Hedesiu, Kauno Alastalo